Literature DB >> 18521597

Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels.

Sandi A Kwee, Tim DeGrado.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18521597     DOI： 10.1007/s00259-008-0781-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  Racial differences in cellular composition of benign prostatic hyperplasia.

Authors:  Y Aoki; Y Arai; H Maeda; K Okubo; K Shinohara
Journal:  Prostate       Date:  2001-12-01       Impact factor: 4.104

Review 2.  Racial differences in pathogenetic mechanisms, prevalence, and progression of benign prostatic hyperplasia.

Authors:  Gerald Hoke; William Baker; Carlton Barnswell; James Bennett; Rodney Davis; Terry Mason; Walter Rayford
Journal:  Urology       Date:  2006-11       Impact factor: 2.649

3.  Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.

Authors:  Sandi A Kwee; Marc N Coel; John Lim; Jehoon P Ko
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

4.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

5.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.

Authors:  A E Wefer; H Hricak; D B Vigneron; F V Coakley; Y Lu; J Wefer; U Mueller-Lisse; P R Carroll; J Kurhanewicz
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

6.  Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.

Authors:  Sandi A Kwee; Hai Wei; Isabell Sesterhenn; David Yun; Marc N Coel
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

7.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.

Authors:  David T Price; R Edward Coleman; Ray P Liao; Cary N Robertson; Thomas J Polascik; Timothy R DeGrado
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

8.  Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer.

Authors:  J B Rietbergen; A E Kruger; R F Hoedemaeker; C H Bangma; W J Kirkels; F H Schröder
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

9.  The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.

Authors:  I Igerc; S Kohlfürst; H J Gallowitsch; S Matschnig; E Kresnik; I Gomez-Segovia; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-11       Impact factor: 9.236

10.  Biodisposition and metabolism of [(18)F]fluorocholine in 9L glioma cells and 9L glioma-bearing fisher rats.

Authors:  Aditya Bansal; Wang Shuyan; Toshiko Hara; Robert A Harris; Timothy R Degrado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-09       Impact factor: 9.236
  10 in total
  13 in total

Review 1.  PET Molecular Imaging-Directed Biopsy: A Review.

Authors:  Baowei Fei; David M Schuster
Journal:  AJR Am J Roentgenol       Date:  2017-05-15       Impact factor: 3.959

Review 2.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

3.  (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.

Authors:  C Sachpekidis; M Eder; K Kopka; W Mier; B A Hadaschik; U Haberkorn; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-12       Impact factor: 9.236

4.  PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

Authors:  Agostino Chiaravalloti; Daniele Di Biagio; Mario Tavolozza; Ferdinando Calabria; Orazio Schillaci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-21       Impact factor: 9.236

5.  Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.

Authors:  Ali Afshar-Oromieh; Henrik Hetzheim; Wolfgang Kübler; Clemens Kratochwil; Frederik L Giesel; Thomas A Hope; Matthias Eder; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-03       Impact factor: 9.236

6.  Molecular imaging and fusion targeted biopsy of the prostate.

Authors:  Baowei Fei; Peter T Nieh; Viraj A Master; Yun Zhang; Adeboye O Osunkoya; David M Schuster
Journal:  Clin Transl Imaging       Date:  2016-12-01

7.  [Potential of PET/MRI for diagnosis of prostate cancer].

Authors:  M C Röthke; A Afshar-Oromieh; H-P Schlemmer
Journal:  Radiologe       Date:  2013-08       Impact factor: 0.635

8.  Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Christian M Zechmann; Anna Malcher; Matthias Eder; Michael Eisenhut; Heinz G Linhart; Tim Holland-Letz; Boris A Hadaschik; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

9.  The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Authors:  Ali Afshar-Oromieh; Eleni Avtzi; Frederik L Giesel; Tim Holland-Letz; Heinz G Linhart; Matthias Eder; Michael Eisenhut; Silvan Boxler; Boris A Hadaschik; Clemens Kratochwil; Wilko Weichert; Klaus Kopka; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

10.  Diagnostic performance of 68Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with 18FEC PET/CT.

Authors:  Manuela A Hoffmann; Matthias Miederer; Helmut J Wieler; Christian Ruf; Frank M Jakobs; Mathias Schreckenberger
Journal:  Oncotarget       Date:  2017-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.